🇺🇸 FDA
Pipeline program

Imiquimod Cream, 3.75%

SYM 2012-01

Phase 3 small_molecule completed

Quick answer

Imiquimod Cream, 3.75% for Actinic Keratosis is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Actinic Keratosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials